Literature DB >> 21452143

[Hepatocellular carcinoma].

David Semela1, Markus Heim.   

Abstract

HCC is the fifth most common tumor worldwide and the third cause of cancer-related deaths. The incidence of HCC is increasing. HCC has become the leading cause of death in patients with liver cirrhosis. Surveillance of patients with chronic liver disease allows early detection of HCC. Surgical resection, liver transplantation and ablative therapies can cure early stage HCC. HCC of intermediate and advanced stage can be treated by chemoembolisation and the tyrosine kinase inhibitor sorafenib, respectively, leading to improved survival. This review summarizes the recent diagnostic and therapeutic developments in the field of HCC.

Entities:  

Mesh:

Year:  2011        PMID: 21452143     DOI: 10.1024/0040-5930/a000153

Source DB:  PubMed          Journal:  Ther Umsch        ISSN: 0040-5930


  5 in total

1.  Hepatocellular carcinoma: clinical study of long-term survival and choice of treatment modalities.

Authors:  Ke-Tong Wu; Cun-Chuan Wang; Li-Gong Lu; Wei-Dong Zhang; Fu-Jun Zhang; Feng Shi; Chuan-Xing Li
Journal:  World J Gastroenterol       Date:  2013-06-21       Impact factor: 5.742

2.  Over-expression of VEGF and MMP-9 in residual tumor cells of hepatocellular carcinoma after embolization with lipidol.

Authors:  Yu-Long Shi; Tao Xu; Le-Ping Li; Xiao-Ping Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2013-02-08

3.  Naringenin (citrus flavonone) induces growth inhibition, cell cycle arrest and apoptosis in human hepatocellular carcinoma cells.

Authors:  Duraikannu Arul; Perumal Subramanian
Journal:  Pathol Oncol Res       Date:  2013-05-10       Impact factor: 3.201

4.  Chloroquine promotes the anticancer effect of TACE in a rabbit VX2 liver tumor model.

Authors:  Lu Gao; Jian-rui Song; Jian-wei Zhang; Xue Zhao; Qiu-dong Zhao; Kai Sun; Wei-jie Deng; Rong Li; Gang Lv; Hong-yan Cheng; Li-xin Wei
Journal:  Int J Biol Sci       Date:  2013-03-28       Impact factor: 6.580

5.  Inherent and acquired resistance to paclitaxel in hepatocellular carcinoma: molecular events involved.

Authors:  Avtar Singh Meena; Aanchal Sharma; Ratna Kumari; Naoshad Mohammad; Shivendra Vikram Singh; Manoj Kumar Bhat
Journal:  PLoS One       Date:  2013-04-16       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.